Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C11H17NO.ClH |
| Molecular Weight | 215.72 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CNC(C)CC1=C(OC)C=CC=C1
InChI
InChIKey=FGSJNNQVSUVTPW-UHFFFAOYSA-N
InChI=1S/C11H17NO.ClH/c1-9(12-2)8-10-6-4-5-7-11(10)13-3;/h4-7,9,12H,8H2,1-3H3;1H
| Molecular Formula | C11H17NO |
| Molecular Weight | 179.2588 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Methoxyphenamine also known as 2-methoxy-N-methylamphetamine (OMMA), is a beta adrenergic receptor agonist nd is used as a bronchodilator to treat asthma, chronic obstructive pulmonary disease (COPD) and postinfectious cough. In addition, methoxyphenamine using is prohibited in sports according to the regulations of the World Anti-Doping Agency (WADA).
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
157 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3625484 |
60.3 mg single, oral dose: 60.3 mg route of administration: Oral experiment type: SINGLE co-administered: |
METHOXYPHENAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1315 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3625484 |
60.3 mg single, oral dose: 60.3 mg route of administration: Oral experiment type: SINGLE co-administered: |
METHOXYPHENAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/3625484 |
60.3 mg single, oral dose: 60.3 mg route of administration: Oral experiment type: SINGLE co-administered: |
METHOXYPHENAMINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Overview
| CYP3A4 | CYP2C9 | CYP2D6 | hERG |
|---|---|---|---|
OverviewOther
| Other Inhibitor | Other Substrate | Other Inducer |
|---|---|---|
Drug as victim
| Target | Modality | Activity | Metabolite | Clinical evidence |
|---|---|---|---|---|
| yes | yes (co-administration study) Comment: Coadministration of quinidine (CYP2D6 inhibitor) increased methoxyphenamine excretion in 32-h urine by 103%. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Chromatographic analysis of phenethylamine-antihistamine combinations using C8, C18 or cyano columns and micellar sodium dodecyl sulfate-pentanol mixtures. | 2001 Apr |
|
| LC-MS method for the determination of albuterol enantiomers in human plasma using manual solid-phase extraction and a non-deuterated internal standard. | 2003 Apr 10 |
|
| Extraction of amphetamines and methylenedioxyamphetamines from urine using a monolithic silica disk-packed spin column and high-performance liquid chromatography-diode array detection. | 2008 Oct 24 |
|
| Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. | 2010 Apr |
|
| Simultaneous determination of eight sympathomimetic amines in urine by gas chromatography/mass spectrometry. | 2010 Jan-Feb |
|
| Efficacy and safety of modified sequential three-step empirical therapy for chronic cough. | 2010 Jul |
Patents
Sample Use Guides
It was revealed, that methoxyphenamine antagonizes the effects of histamine both in vivo and in vitro. In vitro studies indicate a noncompetitive antagonism. Histamine-induced contractions of the isolated guinea-pig ileum were antagonized by methoxyphenamine (10(-5) to 10(-3) M). The histamine log-concentration-response curve was shifted to the right in a parallel manner by methoxyphenamine (10(-5) to 10(-4) M), without depression of maximum responses. However, at higher concentrations, maximum responses were reduced. The slope of the Schild plot was significantly different from -1. The degree of the rightward shift of the concentration-response curves to histamine, produced by 10(-5) M of methoxyphenamine [3.90-(2.83, 4.97) fold], was not significantly different from that produced by 3 x 10(-9) M of mepyramine [4.60-(2.86, 6.52) fold]. Methoxyphenamine, at concentrations of 10(-5) to 3 x 10(-4) M, had no significant effect on responses of guinea-pig ilea to acetylcholine (10(-9) to 10(-5) M).
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:08:47 GMT 2023
by
admin
on
Fri Dec 15 16:08:47 GMT 2023
|
| Record UNII |
52V8BVV7FX
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Fri Dec 15 16:08:47 GMT 2023 , Edited by admin on Fri Dec 15 16:08:47 GMT 2023
|
||
|
CFR |
21 CFR 310.201
Created by
admin on Fri Dec 15 16:08:47 GMT 2023 , Edited by admin on Fri Dec 15 16:08:47 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C005157
Created by
admin on Fri Dec 15 16:08:47 GMT 2023 , Edited by admin on Fri Dec 15 16:08:47 GMT 2023
|
PRIMARY | |||
|
100000085974
Created by
admin on Fri Dec 15 16:08:47 GMT 2023 , Edited by admin on Fri Dec 15 16:08:47 GMT 2023
|
PRIMARY | |||
|
5588-10-3
Created by
admin on Fri Dec 15 16:08:47 GMT 2023 , Edited by admin on Fri Dec 15 16:08:47 GMT 2023
|
PRIMARY | |||
|
65644
Created by
admin on Fri Dec 15 16:08:47 GMT 2023 , Edited by admin on Fri Dec 15 16:08:47 GMT 2023
|
PRIMARY | |||
|
DTXSID301026187
Created by
admin on Fri Dec 15 16:08:47 GMT 2023 , Edited by admin on Fri Dec 15 16:08:47 GMT 2023
|
PRIMARY | |||
|
9859211
Created by
admin on Fri Dec 15 16:08:47 GMT 2023 , Edited by admin on Fri Dec 15 16:08:47 GMT 2023
|
PRIMARY | |||
|
DBSALT002803
Created by
admin on Fri Dec 15 16:08:47 GMT 2023 , Edited by admin on Fri Dec 15 16:08:47 GMT 2023
|
PRIMARY | |||
|
SUB03229MIG
Created by
admin on Fri Dec 15 16:08:47 GMT 2023 , Edited by admin on Fri Dec 15 16:08:47 GMT 2023
|
PRIMARY | |||
|
52V8BVV7FX
Created by
admin on Fri Dec 15 16:08:47 GMT 2023 , Edited by admin on Fri Dec 15 16:08:47 GMT 2023
|
PRIMARY | |||
|
CHEMBL2010507
Created by
admin on Fri Dec 15 16:08:47 GMT 2023 , Edited by admin on Fri Dec 15 16:08:47 GMT 2023
|
PRIMARY | |||
|
226-993-2
Created by
admin on Fri Dec 15 16:08:47 GMT 2023 , Edited by admin on Fri Dec 15 16:08:47 GMT 2023
|
PRIMARY | |||
|
451944
Created by
admin on Fri Dec 15 16:08:47 GMT 2023 , Edited by admin on Fri Dec 15 16:08:47 GMT 2023
|
PRIMARY | RxNorm | ||
|
C83959
Created by
admin on Fri Dec 15 16:08:47 GMT 2023 , Edited by admin on Fri Dec 15 16:08:47 GMT 2023
|
PRIMARY | |||
|
m7341
Created by
admin on Fri Dec 15 16:08:47 GMT 2023 , Edited by admin on Fri Dec 15 16:08:47 GMT 2023
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |